Technology Is Latest Step For Planned Cancer Genome Institute At Fox Chase
6/14/2011

Fox Chase Cancer Center, one of the nation's leading cancer research and treatment institutions, has announced it has entered into an agreement with Life Technologies Corporation that will underpin a new program to provide next-generation sequencing analysis of solid tumors...

News From The Journal Of Clinical Investigation, June 13, 2011
6/14/2011

ONCOLOGY: Small but powerful cancer probe Nanoparticle-based materials are under development for many clinical uses; for example, they are being developed for use as drug-delivery vehicles and diagnostic probes. However, many such materials currently under evaluation in oncology clinical trials are not tumor selective...

Turn The Towns Teal(R) Launches National Campaign To Raise Awareness Of Ovarian Cancer
6/14/2011

Towns nationwide are turning teal to fight ovarian cancer, the leading cause of death from gynecologic cancers in the U.S. There is no early detection test and the symptoms are subtle and often misdiagnosed. Turn The Towns Teal® is a national campaign to promote awareness of the symptoms of ovarian cancer during September, National Ovarian Cancer Awareness Month...

Health Care Expenses Greater For Cancer Survivors
6/14/2011

Approximately 12 million people in the United States are cancer survivors. On average, their medical care costs $4,000 to $5,000 more annually than the care of people who have never had cancer, according to Penn State researchers. Those who are treated for and survive cancer are susceptible to later health complications and their total medical expenses average about $9,300 per year...

Suboptimal Bowel Preparation Substantially Decreases Colonoscopy Effectiveness
6/14/2011

A new study reports that colonoscopies done with suboptimal bowel preparation are associated with relatively high adenoma (precancerous polyp) miss rates, suggesting that suboptimal bowel preparation substantially decreases colonoscopy effectiveness and may mandate an early follow-up examination...

Orexo Announces Successful Completion Of The First Clinical Trial With OX27
6/14/2011

Orexo AB (STO:ORX) announces a successful outcome following completion of the first OX27 pharmacokinetic trial. OX27 is a sublingual tablet developed to optimize the treatment of breakthrough pain in cancer patients. The market for treatment of breakthrough pain in cancer patients is approximately 1.5 billion USD in Europe and United States...

Targeting Tumor Inflammation Could Provide Substantial Therapeutic Benefit
6/14/2011

There is an intimate and complex relationship between inflammation and cancer; and it is well established that tumors secrete many different chemicals that attract host cells which drive inflammation and help to support tumor growth...

New Study Spotlights Potential Of Virus To Treat Certain Lung Cancer Patients
6/14/2011

A type of virus known as the human reovirus possesses a remarkable trait: It can replicate inside and kill cancer cells that feature a common mutation (known as an "activated Ras pathway"), while leaving the body's normal cells alone...

OrSense's Non Invasive Hemoglobin Monitor Has The Potential To Enhance Recruitment Of Blood Donors
6/14/2011

On the World Blood Donors Day, OrSense Ltd., developer of monitors for non-invasive measurements of key blood parameters, presents its non-invasive hemoglobin (Hb) monitor, which holds potential to enhance recruitment and retention of blood donors. Dr...

Towards A More Efficient Therapy For A Specific Form Of Leukemia
6/14/2011

Chronic myeloid leukemia (CML) is a particular form of leukemia or cancer of the bone marrow, which can be treated with targeted imatinib. However, in some cases this medicine has no effect. Researchers at the VIB Vesalius Research Centre, K.U. Leuven, under the direction of Peter Carmeliet, have investigated the role of placental growth factor (PlGF) in mice with CML...